vs
Side-by-side financial comparison of ESCO TECHNOLOGIES INC (ESE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ESCO TECHNOLOGIES INC is the larger business by last-quarter revenue ($289.7M vs $177.4M, roughly 1.6× Pacira BioSciences, Inc.). ESCO TECHNOLOGIES INC runs the higher net margin — 9.9% vs 1.6%, a 8.3% gap on every dollar of revenue. On growth, ESCO TECHNOLOGIES INC posted the faster year-over-year revenue change (17.3% vs 5.0%). Over the past eight quarters, ESCO TECHNOLOGIES INC's revenue compounded faster (7.8% CAGR vs -0.2%).
Esco is a Singaporean brand that develops, manufactures, and sells products and services for laboratories.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ESE vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $289.7M | $177.4M |
| Net Profit | $28.7M | $2.9M |
| Gross Margin | 41.4% | — |
| Operating Margin | 13.2% | 3.9% |
| Net Margin | 9.9% | 1.6% |
| Revenue YoY | 17.3% | 5.0% |
| Net Profit YoY | 22.2% | — |
| EPS (diluted) | $1.11 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $289.7M | $196.9M | ||
| Q3 25 | $286.5M | $179.5M | ||
| Q2 25 | $296.3M | $181.1M | ||
| Q1 25 | $265.5M | $168.9M | ||
| Q4 24 | $247.0M | $187.3M | ||
| Q3 24 | $298.5M | $168.6M | ||
| Q2 24 | $260.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $28.7M | — | ||
| Q3 25 | $218.7M | $5.4M | ||
| Q2 25 | $26.1M | $-4.8M | ||
| Q1 25 | $31.0M | $4.8M | ||
| Q4 24 | $23.5M | — | ||
| Q3 24 | $34.3M | $-143.5M | ||
| Q2 24 | $29.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 79.5% | ||
| Q3 25 | 45.9% | 80.9% | ||
| Q2 25 | 41.2% | 77.4% | ||
| Q1 25 | 41.1% | 79.7% | ||
| Q4 24 | 39.8% | 78.7% | ||
| Q3 24 | 40.1% | 76.9% | ||
| Q2 24 | 39.6% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 13.2% | 1.2% | ||
| Q3 25 | 17.2% | 3.5% | ||
| Q2 25 | 11.2% | 4.7% | ||
| Q1 25 | 15.3% | 1.2% | ||
| Q4 24 | 11.4% | 13.2% | ||
| Q3 24 | 14.8% | -82.8% | ||
| Q2 24 | 14.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 76.3% | 3.0% | ||
| Q2 25 | 8.8% | -2.7% | ||
| Q1 25 | 11.7% | 2.8% | ||
| Q4 24 | 9.5% | — | ||
| Q3 24 | 11.5% | -85.1% | ||
| Q2 24 | 11.2% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $1.11 | $0.05 | ||
| Q3 25 | $8.43 | $0.12 | ||
| Q2 25 | $1.01 | $-0.11 | ||
| Q1 25 | $1.20 | $0.10 | ||
| Q4 24 | $0.91 | $0.38 | ||
| Q3 24 | $1.32 | $-3.11 | ||
| Q2 24 | $1.13 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.8M | $144.3M |
| Total DebtLower is stronger | $145.5M | — |
| Stockholders' EquityBook value | $1.6B | $653.9M |
| Total Assets | $2.4B | $1.2B |
| Debt / EquityLower = less leverage | 0.09× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $103.8M | $238.4M | ||
| Q3 25 | $101.3M | $246.3M | ||
| Q2 25 | $78.7M | $445.9M | ||
| Q1 25 | $57.4M | $493.6M | ||
| Q4 24 | $71.3M | $484.6M | ||
| Q3 24 | $66.0M | $453.8M | ||
| Q2 24 | $63.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $145.5M | $372.2M | ||
| Q3 25 | $186.0M | $376.7M | ||
| Q2 25 | $525.0M | $580.5M | ||
| Q1 25 | $88.0M | $583.4M | ||
| Q4 24 | $112.0M | $585.3M | ||
| Q3 24 | $122.0M | — | ||
| Q2 24 | $173.0M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.6B | $693.1M | ||
| Q3 25 | $1.5B | $727.2M | ||
| Q2 25 | $1.3B | $757.8M | ||
| Q1 25 | $1.3B | $798.5M | ||
| Q4 24 | $1.2B | $778.3M | ||
| Q3 24 | $1.2B | $749.6M | ||
| Q2 24 | $1.2B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.4B | $1.3B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $2.5B | $1.5B | ||
| Q1 25 | $1.8B | $1.6B | ||
| Q4 24 | $1.8B | $1.6B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.8B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.09× | 0.54× | ||
| Q3 25 | 0.12× | 0.52× | ||
| Q2 25 | 0.40× | 0.77× | ||
| Q1 25 | 0.07× | 0.73× | ||
| Q4 24 | 0.09× | 0.75× | ||
| Q3 24 | 0.10× | — | ||
| Q2 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.9M | — |
| Free Cash FlowOCF − Capex | $63.0M | — |
| FCF MarginFCF / Revenue | 21.7% | — |
| Capex IntensityCapex / Revenue | 2.0% | — |
| Cash ConversionOCF / Net Profit | 2.40× | — |
| TTM Free Cash FlowTrailing 4 quarters | $239.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $68.9M | $43.7M | ||
| Q3 25 | $109.9M | $60.8M | ||
| Q2 25 | $73.7M | $12.0M | ||
| Q1 25 | $24.1M | $35.5M | ||
| Q4 24 | $34.2M | $33.1M | ||
| Q3 24 | $72.1M | $53.9M | ||
| Q2 24 | $36.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $63.0M | $43.5M | ||
| Q3 25 | $97.8M | $57.0M | ||
| Q2 25 | $64.9M | $9.3M | ||
| Q1 25 | $14.0M | $26.9M | ||
| Q4 24 | $29.0M | $31.0M | ||
| Q3 24 | $60.9M | $49.8M | ||
| Q2 24 | $27.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 21.7% | 22.1% | ||
| Q3 25 | 34.1% | 31.7% | ||
| Q2 25 | 21.9% | 5.1% | ||
| Q1 25 | 5.3% | 15.9% | ||
| Q4 24 | 11.7% | 16.6% | ||
| Q3 24 | 20.4% | 29.6% | ||
| Q2 24 | 10.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 4.2% | 2.2% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | 3.8% | 5.1% | ||
| Q4 24 | 2.1% | 1.1% | ||
| Q3 24 | 3.8% | 2.4% | ||
| Q2 24 | 3.3% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.40× | — | ||
| Q3 25 | 0.50× | 11.20× | ||
| Q2 25 | 2.83× | — | ||
| Q1 25 | 0.78× | 7.37× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 1.24× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESE
| US Government | $98.0M | 34% |
| Utility Solutions Group | $87.5M | 30% |
| RF Shielding And Test | $58.3M | 20% |
| Commercial | $45.8M | 16% |
| Related Party | $1.3M | 0% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
